Legumain activated doxorubicin derivative as well as preparation method and application thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9982011
SERIAL NO

14655869

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO LTDSHANGHAI

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Liu, Cheng Shanghai, CN 258 1087
Liu, Yuan Shanghai, CN 306 2821

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 29, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 29, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00